NeuroBo Pharmaceuticals(NRBO) - 2025 Q4 - Annual Results

Exhibit 99.1 MetaVia Reports Year End 2025 Financial Results and Provides Corporate Update Mr. Kim continued, "Beyond DA-1726, we continued to advance vanoglipel (DA- 1241), a novel G-Protein-Coupled Receptor 119 (GPR119) agonist, with the presentation of positive Phase 2a data at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2025, highlighting clinically meaningful improvements in glucose control, liver health and plasma lipidomic profiles over 16 weeks. In parallel, r ...